APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Idiopathic Constipation Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Chronic Idiopathic Constipation Drugs Market Outlook and Growth Opportunities 2026

20 December 2025207 pages

Choose your research edition.

Industry ResearchChronic Idiopathic Constipation Drugs Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Idiopathic Constipation Drugs Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Chronic Idiopathic Constipation Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Idiopathic Constipation Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Idiopathic Constipation Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Chronic Idiopathic Constipation Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Idiopathic Constipation Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Chronic Idiopathic Constipation Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Chronic Idiopathic Constipation Drugs market include Sanofi, Merck, Eli Lilly, Pfizer, Glaxosmithkline, Bayer AG, Theravance Biopharma Inc, Synergy Pharmaceuticals and Sucampo Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Idiopathic Constipation Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Idiopathic Constipation Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Idiopathic Constipation Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Idiopathic Constipation Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Idiopathic Constipation Drugs Segment by Company

Sanofi

Merck

Eli Lilly

Pfizer

Glaxosmithkline

Bayer AG

Theravance Biopharma Inc

Synergy Pharmaceuticals

Sucampo Pharmaceuticals Inc

Salix Pharmaceuticals Ltd

Roche Holding AG

Progenics Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Ferring International Center S.A

Daiichi Sankyo

Cosmo Pharmaceuticals SA

Chugai Pharmaceutical

Bausch Health

Allergens

Chronic Idiopathic Constipation Drugs Segment by Type

Linaclotide

Lubiprostone

Others

Chronic Idiopathic Constipation Drugs Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Chronic Idiopathic Constipation Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Chronic Idiopathic Constipation Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Chronic Idiopathic Constipation Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Chronic Idiopathic Constipation Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Chronic Idiopathic Constipation Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Idiopathic Constipation Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Idiopathic Constipation Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Idiopathic Constipation Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Idiopathic Constipation Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chronic Idiopathic Constipation Drugs industry.

Chapter 3: Detailed analysis of Chronic Idiopathic Constipation Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Chronic Idiopathic Constipation Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Chronic Idiopathic Constipation Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Chronic Idiopathic Constipation Drugs Industry Trends Table 2. Chronic Idiopathic Constipation Drugs Industry Drivers Table 3. Chronic Idiopathic Constipation Drugs Industry Opportunities and Challenges Table 4. Chronic Idiopathic Constipation Drugs Industry Restraints Table 5. Global Chronic Idiopathic Constipation Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Chronic Idiopathic Constipation Drugs Revenue Share by Company (2021-2026) Table 7. Global Chronic Idiopathic Constipation Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Chronic Idiopathic Constipation Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Chronic Idiopathic Constipation Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Chronic Idiopathic Constipation Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Chronic Idiopathic Constipation Drugs Company, Product Type & Application Table 13. Global Chronic Idiopathic Constipation Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Idiopathic Constipation Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Linaclotide Table 18. Significant Companies of Lubiprostone Table 19. Significant Companies of Others Table 20. Global Chronic Idiopathic Constipation Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Chronic Idiopathic Constipation Drugs Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Chronic Idiopathic Constipation Drugs Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Chronic Idiopathic Constipation Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Chronic Idiopathic Constipation Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Chronic Idiopathic Constipation Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Type (2021-2026) Table 29. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Online Pharmacies Table 32. Significant Companies of Hospital Pharmacies Table 33. Global Chronic Idiopathic Constipation Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Chronic Idiopathic Constipation Drugs Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Chronic Idiopathic Constipation Drugs Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Chronic Idiopathic Constipation Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Chronic Idiopathic Constipation Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Chronic Idiopathic Constipation Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Application (2021-2026) Table 42. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Application (2027-2032) Table 43. Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Chronic Idiopathic Constipation Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Region (2021-2026) Table 46. Global Chronic Idiopathic Constipation Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Region (2027-2032) Table 48. Global Chronic Idiopathic Constipation Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Chronic Idiopathic Constipation Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Region (2021-2026) Table 51. Global Chronic Idiopathic Constipation Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Region (2027-2032) Table 53. Global Chronic Idiopathic Constipation Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Chronic Idiopathic Constipation Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Chronic Idiopathic Constipation Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Chronic Idiopathic Constipation Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026) & (K Units) Table 58. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2021-2026) Table 59. Global Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Country (2027-2032) Table 61. Global Chronic Idiopathic Constipation Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Chronic Idiopathic Constipation Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Chronic Idiopathic Constipation Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Chronic Idiopathic Constipation Drugs Sales Value Market Share by Country (2027-2032) Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Sanofi Chronic Idiopathic Constipation Drugs Product Portfolio Table 69. Sanofi Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Merck Chronic Idiopathic Constipation Drugs Product Portfolio Table 74. Merck Recent Development Table 75. Eli Lilly Company Information Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Eli Lilly Chronic Idiopathic Constipation Drugs Product Portfolio Table 79. Eli Lilly Recent Development Table 80. Pfizer Company Information Table 81. Pfizer Business Overview Table 82. Pfizer Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Pfizer Chronic Idiopathic Constipation Drugs Product Portfolio Table 84. Pfizer Recent Development Table 85. Glaxosmithkline Company Information Table 86. Glaxosmithkline Business Overview Table 87. Glaxosmithkline Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Glaxosmithkline Chronic Idiopathic Constipation Drugs Product Portfolio Table 89. Glaxosmithkline Recent Development Table 90. Bayer AG Company Information Table 91. Bayer AG Business Overview Table 92. Bayer AG Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bayer AG Chronic Idiopathic Constipation Drugs Product Portfolio Table 94. Bayer AG Recent Development Table 95. Theravance Biopharma Inc Company Information Table 96. Theravance Biopharma Inc Business Overview Table 97. Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Product Portfolio Table 99. Theravance Biopharma Inc Recent Development Table 100. Synergy Pharmaceuticals Company Information Table 101. Synergy Pharmaceuticals Business Overview Table 102. Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Product Portfolio Table 104. Synergy Pharmaceuticals Recent Development Table 105. Sucampo Pharmaceuticals Inc Company Information Table 106. Sucampo Pharmaceuticals Inc Business Overview Table 107. Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio Table 109. Sucampo Pharmaceuticals Inc Recent Development Table 110. Salix Pharmaceuticals Ltd Company Information Table 111. Salix Pharmaceuticals Ltd Business Overview Table 112. Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Product Portfolio Table 114. Salix Pharmaceuticals Ltd Recent Development Table 115. Roche Holding AG Company Information Table 116. Roche Holding AG Business Overview Table 117. Roche Holding AG Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Roche Holding AG Chronic Idiopathic Constipation Drugs Product Portfolio Table 119. Roche Holding AG Recent Development Table 120. Progenics Pharmaceuticals Inc Company Information Table 121. Progenics Pharmaceuticals Inc Business Overview Table 122. Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio Table 124. Progenics Pharmaceuticals Inc Recent Development Table 125. Ironwood Pharmaceuticals Inc Company Information Table 126. Ironwood Pharmaceuticals Inc Business Overview Table 127. Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio Table 129. Ironwood Pharmaceuticals Inc Recent Development Table 130. Ferring International Center S.A Company Information Table 131. Ferring International Center S.A Business Overview Table 132. Ferring International Center S.A Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Ferring International Center S.A Chronic Idiopathic Constipation Drugs Product Portfolio Table 134. Ferring International Center S.A Recent Development Table 135. Daiichi Sankyo Company Information Table 136. Daiichi Sankyo Business Overview Table 137. Daiichi Sankyo Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Daiichi Sankyo Chronic Idiopathic Constipation Drugs Product Portfolio Table 139. Daiichi Sankyo Recent Development Table 140. Cosmo Pharmaceuticals SA Company Information Table 141. Cosmo Pharmaceuticals SA Business Overview Table 142. Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Product Portfolio Table 144. Cosmo Pharmaceuticals SA Recent Development Table 145. Chugai Pharmaceutical Company Information Table 146. Chugai Pharmaceutical Business Overview Table 147. Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Product Portfolio Table 149. Chugai Pharmaceutical Recent Development Table 150. Bausch Health Company Information Table 151. Bausch Health Business Overview Table 152. Bausch Health Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Bausch Health Chronic Idiopathic Constipation Drugs Product Portfolio Table 154. Bausch Health Recent Development Table 155. Allergens Company Information Table 156. Allergens Business Overview Table 157. Allergens Chronic Idiopathic Constipation Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Allergens Chronic Idiopathic Constipation Drugs Product Portfolio Table 159. Allergens Recent Development Table 160. Key Raw Materials Table 161. Raw Materials Key Suppliers Table 162. Chronic Idiopathic Constipation Drugs Distributors List Table 163. Chronic Idiopathic Constipation Drugs Customers List Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Chronic Idiopathic Constipation Drugs Product Image Figure 2. Global Chronic Idiopathic Constipation Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Idiopathic Constipation Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Chronic Idiopathic Constipation Drugs Sales (2021-2032) & (K Units) Figure 5. Global Chronic Idiopathic Constipation Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Chronic Idiopathic Constipation Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Linaclotide Image Figure 10. Lubiprostone Image Figure 11. Others Image Figure 12. Global Chronic Idiopathic Constipation Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Chronic Idiopathic Constipation Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Chronic Idiopathic Constipation Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Chronic Idiopathic Constipation Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Type (2021-2032) Figure 18. Retail Pharmacies Image Figure 19. Online Pharmacies Image Figure 20. Hospital Pharmacies Image Figure 21. Global Chronic Idiopathic Constipation Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Chronic Idiopathic Constipation Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Chronic Idiopathic Constipation Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Chronic Idiopathic Constipation Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Chronic Idiopathic Constipation Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Chronic Idiopathic Constipation Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Chronic Idiopathic Constipation Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Chronic Idiopathic Constipation Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Chronic Idiopathic Constipation Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Chronic Idiopathic Constipation Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Chronic Idiopathic Constipation Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Chronic Idiopathic Constipation Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Chronic Idiopathic Constipation Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Chronic Idiopathic Constipation Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Chronic Idiopathic Constipation Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Chronic Idiopathic Constipation Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Chronic Idiopathic Constipation Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Chronic Idiopathic Constipation Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Chronic Idiopathic Constipation Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Linaclotide
  • Lubiprostone
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Sanofi
  • Merck
  • Eli Lilly
  • Pfizer
  • Glaxosmithkline
  • Bayer AG
  • Theravance Biopharma Inc
  • Synergy Pharmaceuticals
  • Sucampo Pharmaceuticals Inc
  • Salix Pharmaceuticals Ltd
  • Roche Holding AG
  • Progenics Pharmaceuticals Inc
  • Ironwood Pharmaceuticals Inc
  • Ferring International Center S.A
  • Daiichi Sankyo
  • Cosmo Pharmaceuticals SA
  • Chugai Pharmaceutical
  • Bausch Health
  • Allergens

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Chronic Idiopathic Constipation Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Chronic Idiopathic Constipation Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Chronic Idiopathic Constipation Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Chronic Idiopathic Constipation Drugs Market Dynamics
  1. 2.1 Chronic Idiopathic Constipation Drugs Industry Trends
  2. 2.2 Chronic Idiopathic Constipation Drugs Industry Drivers
  3. 2.3 Chronic Idiopathic Constipation Drugs Industry Opportunities and Challenges
  4. 2.4 Chronic Idiopathic Constipation Drugs Industry Restraints
3 Chronic Idiopathic Constipation Drugs Market by Company
  1. 3.1 Global Chronic Idiopathic Constipation Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Chronic Idiopathic Constipation Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Chronic Idiopathic Constipation Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Chronic Idiopathic Constipation Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Chronic Idiopathic Constipation Drugs Company Ranking (2024-2026)
  6. 3.6 Global Chronic Idiopathic Constipation Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Chronic Idiopathic Constipation Drugs Company Product Type and Application
  8. 3.8 Global Chronic Idiopathic Constipation Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Chronic Idiopathic Constipation Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Chronic Idiopathic Constipation Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Chronic Idiopathic Constipation Drugs Market by Type
  1. 4.1 Chronic Idiopathic Constipation Drugs Type Introduction
  2. 4.1.1 Linaclotide
  3. 4.1.2 Lubiprostone
  4. 4.1.3 Others
  5. 4.2 Global Chronic Idiopathic Constipation Drugs Sales Volume by Type
  6. 4.2.1 Global Chronic Idiopathic Constipation Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Chronic Idiopathic Constipation Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Chronic Idiopathic Constipation Drugs Sales Value by Type
  10. 4.3.1 Global Chronic Idiopathic Constipation Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Chronic Idiopathic Constipation Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Chronic Idiopathic Constipation Drugs Sales Value Share by Type (2021-2032)
5 Chronic Idiopathic Constipation Drugs Market by Application
  1. 5.1 Chronic Idiopathic Constipation Drugs Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Chronic Idiopathic Constipation Drugs Sales Volume by Application
  6. 5.2.1 Global Chronic Idiopathic Constipation Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chronic Idiopathic Constipation Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Chronic Idiopathic Constipation Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Chronic Idiopathic Constipation Drugs Sales Value by Application
  10. 5.3.1 Global Chronic Idiopathic Constipation Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chronic Idiopathic Constipation Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Chronic Idiopathic Constipation Drugs Sales Value Share by Application (2021-2032)
6 Chronic Idiopathic Constipation Drugs Regional Sales and Value Analysis
  1. 6.1 Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Idiopathic Constipation Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Idiopathic Constipation Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Chronic Idiopathic Constipation Drugs Sales by Region (2027-2032)
  5. 6.3 Global Chronic Idiopathic Constipation Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Chronic Idiopathic Constipation Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Chronic Idiopathic Constipation Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Chronic Idiopathic Constipation Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Chronic Idiopathic Constipation Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Chronic Idiopathic Constipation Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Chronic Idiopathic Constipation Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Chronic Idiopathic Constipation Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Chronic Idiopathic Constipation Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Chronic Idiopathic Constipation Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Chronic Idiopathic Constipation Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Chronic Idiopathic Constipation Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Chronic Idiopathic Constipation Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Chronic Idiopathic Constipation Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Chronic Idiopathic Constipation Drugs Sales Value Share by Country, 2025 VS 2032
7 Chronic Idiopathic Constipation Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Chronic Idiopathic Constipation Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Chronic Idiopathic Constipation Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Chronic Idiopathic Constipation Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Chronic Idiopathic Constipation Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Chronic Idiopathic Constipation Drugs Sales by Country (2027-2032)
  6. 7.4 Global Chronic Idiopathic Constipation Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Chronic Idiopathic Constipation Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Chronic Idiopathic Constipation Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Chronic Idiopathic Constipation Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Chronic Idiopathic Constipation Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Chronic Idiopathic Constipation Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Chronic Idiopathic Constipation Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Chronic Idiopathic Constipation Drugs Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Chronic Idiopathic Constipation Drugs Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Chronic Idiopathic Constipation Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Glaxosmithkline
  26. 8.5.1 Glaxosmithkline Company Information
  27. 8.5.2 Glaxosmithkline Business Overview
  28. 8.5.3 Glaxosmithkline Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Glaxosmithkline Chronic Idiopathic Constipation Drugs Product Portfolio
  30. 8.5.5 Glaxosmithkline Recent Developments
  31. 8.6 Bayer AG
  32. 8.6.1 Bayer AG Company Information
  33. 8.6.2 Bayer AG Business Overview
  34. 8.6.3 Bayer AG Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer AG Chronic Idiopathic Constipation Drugs Product Portfolio
  36. 8.6.5 Bayer AG Recent Developments
  37. 8.7 Theravance Biopharma Inc
  38. 8.7.1 Theravance Biopharma Inc Company Information
  39. 8.7.2 Theravance Biopharma Inc Business Overview
  40. 8.7.3 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Theravance Biopharma Inc Chronic Idiopathic Constipation Drugs Product Portfolio
  42. 8.7.5 Theravance Biopharma Inc Recent Developments
  43. 8.8 Synergy Pharmaceuticals
  44. 8.8.1 Synergy Pharmaceuticals Company Information
  45. 8.8.2 Synergy Pharmaceuticals Business Overview
  46. 8.8.3 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Synergy Pharmaceuticals Chronic Idiopathic Constipation Drugs Product Portfolio
  48. 8.8.5 Synergy Pharmaceuticals Recent Developments
  49. 8.9 Sucampo Pharmaceuticals Inc
  50. 8.9.1 Sucampo Pharmaceuticals Inc Company Information
  51. 8.9.2 Sucampo Pharmaceuticals Inc Business Overview
  52. 8.9.3 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sucampo Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
  54. 8.9.5 Sucampo Pharmaceuticals Inc Recent Developments
  55. 8.10 Salix Pharmaceuticals Ltd
  56. 8.10.1 Salix Pharmaceuticals Ltd Company Information
  57. 8.10.2 Salix Pharmaceuticals Ltd Business Overview
  58. 8.10.3 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Salix Pharmaceuticals Ltd Chronic Idiopathic Constipation Drugs Product Portfolio
  60. 8.10.5 Salix Pharmaceuticals Ltd Recent Developments
  61. 8.11 Roche Holding AG
  62. 8.11.1 Roche Holding AG Company Information
  63. 8.11.2 Roche Holding AG Business Overview
  64. 8.11.3 Roche Holding AG Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Roche Holding AG Chronic Idiopathic Constipation Drugs Product Portfolio
  66. 8.11.5 Roche Holding AG Recent Developments
  67. 8.12 Progenics Pharmaceuticals Inc
  68. 8.12.1 Progenics Pharmaceuticals Inc Company Information
  69. 8.12.2 Progenics Pharmaceuticals Inc Business Overview
  70. 8.12.3 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Progenics Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
  72. 8.12.5 Progenics Pharmaceuticals Inc Recent Developments
  73. 8.13 Ironwood Pharmaceuticals Inc
  74. 8.13.1 Ironwood Pharmaceuticals Inc Company Information
  75. 8.13.2 Ironwood Pharmaceuticals Inc Business Overview
  76. 8.13.3 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Ironwood Pharmaceuticals Inc Chronic Idiopathic Constipation Drugs Product Portfolio
  78. 8.13.5 Ironwood Pharmaceuticals Inc Recent Developments
  79. 8.14 Ferring International Center S.A
  80. 8.14.1 Ferring International Center S.A Company Information
  81. 8.14.2 Ferring International Center S.A Business Overview
  82. 8.14.3 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Ferring International Center S.A Chronic Idiopathic Constipation Drugs Product Portfolio
  84. 8.14.5 Ferring International Center S.A Recent Developments
  85. 8.15 Daiichi Sankyo
  86. 8.15.1 Daiichi Sankyo Company Information
  87. 8.15.2 Daiichi Sankyo Business Overview
  88. 8.15.3 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Daiichi Sankyo Chronic Idiopathic Constipation Drugs Product Portfolio
  90. 8.15.5 Daiichi Sankyo Recent Developments
  91. 8.16 Cosmo Pharmaceuticals SA
  92. 8.16.1 Cosmo Pharmaceuticals SA Company Information
  93. 8.16.2 Cosmo Pharmaceuticals SA Business Overview
  94. 8.16.3 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Cosmo Pharmaceuticals SA Chronic Idiopathic Constipation Drugs Product Portfolio
  96. 8.16.5 Cosmo Pharmaceuticals SA Recent Developments
  97. 8.17 Chugai Pharmaceutical
  98. 8.17.1 Chugai Pharmaceutical Company Information
  99. 8.17.2 Chugai Pharmaceutical Business Overview
  100. 8.17.3 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Chugai Pharmaceutical Chronic Idiopathic Constipation Drugs Product Portfolio
  102. 8.17.5 Chugai Pharmaceutical Recent Developments
  103. 8.18 Bausch Health
  104. 8.18.1 Bausch Health Company Information
  105. 8.18.2 Bausch Health Business Overview
  106. 8.18.3 Bausch Health Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Bausch Health Chronic Idiopathic Constipation Drugs Product Portfolio
  108. 8.18.5 Bausch Health Recent Developments
  109. 8.19 Allergens
  110. 8.19.1 Allergens Company Information
  111. 8.19.2 Allergens Business Overview
  112. 8.19.3 Allergens Chronic Idiopathic Constipation Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Allergens Chronic Idiopathic Constipation Drugs Product Portfolio
  114. 8.19.5 Allergens Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Idiopathic Constipation Drugs Value Chain Analysis
  2. 9.1.1 Chronic Idiopathic Constipation Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Idiopathic Constipation Drugs Sales Mode & Process
  6. 9.2 Chronic Idiopathic Constipation Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Idiopathic Constipation Drugs Distributors
  9. 9.2.3 Chronic Idiopathic Constipation Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst